-

SHAREHOLDER ALERT: Robbins LLP is Investigating CleanSpark, Inc. (CLSK) on Behalf of Shareholders

SAN DIEGO & WOODS CROSS, Utah--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating CleanSpark, Inc. (NASDAQ: CLSK) to determine whether certain CleanSpark officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. CleanSpark provides advanced software and controls technology solutions, including end-to-end microgrid energy modeling, energy market communications, and energy management solutions.

If you suffered a loss due to CleanSpark, Inc.'s misconduct, click here.

CleanSpark, Inc. (CLSK) May Have Misled Investors About its Related Party Transactions and its Customer and Contract Figures

On December 31, 2020, CleanSpark issued a press release touting its achievements and "a number of significant wins for the Company." As for outlook, the Company "forecast[ed] that our second and third fiscal quarters will again be our strongest" and projected it would "generate $20 million in revenue related to our current business segments and we expect the recent acquisition of ATL Data Center to contribute a minimum of $10 million in additional Bitcoin-based (BTC-USD) revenues for 2021."

On January 14, 2021, Culper Research published a report alleging that CleanSpark had "fabricated key elements of its business, including purported customers and contracts" and that it is "rife with undisclosed related party transactions." Specifically, the report alleged that the acquisition of ATL Data Centers, LLC "is another Gutless Promotion Attempt" and that the Company's acquisition of p2k Labs was "an undisclosed related party transaction that apparently fabricated its customers." On this news, the Company's share price fell $3.63, or 9%, to close at $35.71 per share on January 14, 2021. The stock now trades at just around $16.00.

CleanSpark, Inc. (CLSK) Shareholders Have Options

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against CleanSpark, Inc. settles or to receive free alerts about corporate executives engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges BBNX Stockholders Who Lost Money Investing in Beta Bionics, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). Beta Bionics is a commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump (...

Robbins LLP Urges HIMS Stockholders Who Lost Money Investing in Hims & Hers Health, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). Hims operates a health and wellness platform that connects consumers to licensed healthcare professionals.The complaint alleges that Hims & Hers shared customers' protected health...

Robbins LLP Urges UNCY Stockholders Who Lost Money Investing in Unicycive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies for the treatment of kidney diseases.The complaint alleges that Unicycive failed to properly inspect its t...
Back to Newsroom